title: Erythrocytapheresis plus erythropoietin: an alternative therapy for selected patients with hemochromatosis and severe organ damage.
abstract: We report the efficacy, tolerability and cost of erythocytoapheresis plus recombinant human erythropoietin (rHuEPO) in three patients with severe hereditary hemochromatosis (HH). Results indicate that this regimen could be a valid therapeutic alternative in complicated HH patients. Its cost, however, limits its use to patients whose clinical conditions prevent a proper phlebotomy regimen.
authors.forename: Raffaella
authors.initials: R
authors.lastname: Mariani
authors.forename: Sara
authors.initials: S
authors.lastname: Pelucchi
authors.forename: Paolo
authors.initials: P
authors.lastname: Perseghin
authors.forename: Chiara
authors.initials: C
authors.lastname: Corengia
authors.forename: Alberto
authors.initials: A
authors.lastname: Piperno
mesh_terms: D000328:Adult; D003131:Combined Modality Therapy; D016238:Cytapheresis / Q000191:economics / Q000379:methods*; D004921:Erythropoietin / Q000191:economics / Q000627:therapeutic use*; D006432:Hemochromatosis / Q000097:blood / Q000188:drug therapy / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D000071020:Hemochromatosis Protein; D015395:Histocompatibility Antigens Class I / Q000235:genetics; D006801:Humans; D019190:Iron Overload / Q000209:etiology / Q000628:therapy; D008103:Liver Cirrhosis / Q000209:etiology; D008297:Male; D008565:Membrane Proteins / Q000235:genetics; D008875:Middle Aged; D011994:Recombinant Proteins; D016896:Treatment Outcome
chemical_list: C103673:HFE protein, human; D000071020:Hemochromatosis Protein; D015395:Histocompatibility Antigens Class I; D008565:Membrane Proteins; D011994:Recombinant Proteins; D004921:Erythropoietin